PRP Success Rate for Hair: What Trials Actually Measured

There is no published success rate for PRP hair treatment. That is the direct answer, and it is not a technicality: the randomized trials measured changes in hair density in treated areas over a few months — they did not define “success,” follow patients for years, or count how many people looked in a mirror and were satisfied. Any percentage a clinic quotes you is either a misreading of those density numbers or a figure from the clinic's own unaudited records. Here is what the record actually holds.

The best pooled numbers, stated exactly

The most recent meta-analysis of randomized trials (Yao et al., PLoS One, 28 August 2024) compared PRP added to topical minoxidil against the topical alone across five trials. Hair density with PRP was better by 11.07 hairs per cm² at one month, 21.81 at three months and 17.80 at five to six months — with the five-to-six-month figure carrying a 95% confidence interval of 7.91 to 27.69. Adverse events were statistically comparable between groups. Those are honest, positive numbers, and they come with the analysts' own warning label:

“Very low-quality evidence shows that the addition of injectable PRP to topical Minoxidil may improve outcomes in patients with androgenetic alopecia.” — Yao et al., PLoS One, 28 August 2024

Three of the five trials were judged at high risk of bias, one more raised “some concerns,” the PRP preparation methods differed between trials, and follow-up stopped at six months. “May improve,” graded that way, is the ceiling of what anyone can honestly promise you. Everything in this reading hangs off that pooled analysis and its predecessors, because they are the only place the category's numbers were collected under rules — every figure here is theirs, dated, not ours.

Why “density improved” is not “it worked for X% of men”

A success rate needs a definition of success, a denominator, and time — and the trials supply none of the three in the form marketing uses. Density is an average across a study group: a +17.8 average is compatible with some scalps changing visibly, many barely, and some not at all, and the trials were too small to say which you'd be. Six months of follow-up cannot speak to year two, while the sold protocol quietly assumes maintenance forever — the cost arithmetic reading shows what that assumption bills. And “versus minoxidil alone” means the trials mostly tested PRP as a booster on top of a drug, not as the standalone treatment consultations tend to describe.

Why the pooled trials disagree with each other

Even inside one meta-analysis, the trials pull apart — the three-month pooled figure carried moderate statistical heterogeneity and the five-to-six month figure high heterogeneity (I² of 57% and 80% in the analysis) — and the analysts named the likeliest reason: “heterogeneity in PRP preparation methods.” PRP is not one product. Spin speeds, spin counts, activation steps, platelet concentrations and injection volumes all differ between clinics and between trials, and nobody has standardized the recipe. Practically, that means a positive pooled average cannot certify the particular syringe your clinic prepares — the version of PRP that earned the numbers may not be the version you are buying.

What a trial would need before “success rate” meant something

The phrase would need machinery none of the current trials built: a definition of success fixed before the data came in (say, a visible-density threshold at twelve months, judged blind); a sham-injection control arm so the needle ritual itself doesn't flatter the result; follow-up past a year, since the sold protocol runs indefinitely; a standardized preparation others could replicate; and funding independent of anyone selling centrifuges or sessions. Hold clinic claims to that shape and the conversation gets honest fast — most percentage claims dissolve into “our patients seem happy,” which is a different sentence.

How to hear a clinic's percentage

When a consultation says “we see improvement in 80% of patients,” the useful response is three questions. Measured how — calipers and photographs on a fixed protocol, or impressions? Compared with what — because shedding cycles and concurrent drug use flatter any before/after? And published where — because if the answer is nowhere, the number is a sales figure wearing a lab coat. A clinic doing careful work will answer without flinching; a funnel will change the subject to a package discount.

The percentage with the strongest gravity: the transplant add-on

The place a success-rate figure works hardest is the transplant consultation, where PRP is offered as an add-on to protect or accelerate grafts — usually at the same per-session prices as standalone treatment. Note what changed: the trials in the 2024 pooled analysis studied PRP for androgenetic alopecia on unoperated scalps, not for graft survival after surgery, so even the low-certainty numbers above stop applying the moment the pitch becomes post-surgical. That decision has its own thinner record, which we cover separately in the PRP after a hair transplant reading; the short version is that the add-on's evidence is weaker than the standalone evidence, while its price is the same.

Where that leaves a decision

PRP sits in the middle of the non-drug menu: more evidence than the exosome and stem-cell offers the FDA warns about, less certainty than the approved drugs, and a recurring price above everything on our laser cap for hair growth assessment. If you go ahead, go ahead knowing the honest sentence: plausible benefit, low-certainty evidence, indefinite maintenance — and let a dermatologist who has actually diagnosed your hair loss say whether that trade makes sense for you.